MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Drug-induced parkinsonism(DIP)"

  • 2016 International Congress

    Drug induced parkinsonism: Role of functional imaging and follow up

    A.S. Shetty, H.J. Shah, V.R. Lele, P.M. Wadia (Mumbai, India)

    Objective: Retrospective study of the outcome of patients with new onset parkinsonism with a history of exposure of a drug known to cause parkinsonism prior…
  • 2016 International Congress

    Valproate-induced reversible parkinsonism – A case series

    R.M. Simões, N. Inácio, V.B. Silva, A. Arraiolos, P. Alegria, N. Canas, J. Vale (Loures, Portugal)

    Objective: To describe a case series of valproate (VPA)-induced parkinsonism and increase awareness for this condition. Background: VPA as a cause of parkinsonism has been…
  • 2016 International Congress

    Effect of intra-striatal 6-OHDA lesion on extra-striatal structures in the mouse

    B. Becker, M. Demirbas, C. Beyer, S. Tan, M. Kipp (Aachen, Germany)

    Objective: Characterization of extra-striatal manifestations in the 6-hydroxydopamine (6-OHDA) Parkinson's disease (PD) animal model. Background: PD is a neurodegenerative disorder characterized by progressive loss of…
  • 2016 International Congress

    A comparative study of clinical profile of patients of drug induced parkinsonism with idiopathic Parkinson’s disease

    S. Kushwaha, R. Mistry, A. Anthony, S. Khurana (Delhi, India)

    Objective: Drug induced parkinsonism (DIP), caused by various group of drugs, is second most common etiology of parkinsonism after Idiopathic Parkinson's disease (IPD). No major…
  • 2016 International Congress

    Incidental finding of drug-induced movement disorder

    G. Avagyan, H. Manvelyan, A. Nazaryan (Yerevan, Armenia)

    Objective: Recognizing a drug-induced movement disorder is critical as only stopping using over the counter dopamine-blocking medications such as metoclopramide can reverse or improve clinical…
  • 2016 International Congress

    Three distinct cases of methamphetamine induced movement disorders

    T.A. Clark, J. Kraakevik (Portland, OR, USA)

    Objective: To detail three cases of methamphetamine induced movement disorders with unique clinical phenotypes. Background: MA is an addictive psychostimulant that affects both the central…
  • 2016 International Congress

    Valproate-associated parkinsonism – A critical review of the literature

    F. Brugger, K.P. Bhatia, F.M.C. Besag (St. Gallen, Switzerland)

    Objective: To provide a critical review of the existing literature on valproate-associated parkinsonism and to discuss possible mechanisms. Background: Valproate was first approved as an…
  • 2016 International Congress

    MEK inhibitors have antidyskinetic effects in hemiParkinsonian rats that are associated with critical neurochemical alterations in the striatum

    G. Chen, S. Nie, K. Ma, C. Han, Y. Xu, Z. Zhang, S.M. Papa, X. Cao (Wuhan, People's Republic of China)

    Objective: To examine the effects of MEK inhibitors PD98059 and U0126 on L-DOPA-induced dyskinesia and the induced molecular changes. Background: L-DOPA-induced dyskinesia (LID) represents one…
  • 2016 International Congress

    Persistent drug-induced parkinsonism with normal dopamine transporter imaging

    J.W. Lee, J.Y. Hong, J.S. Oh, I. Lee, J.S. Kim, Y.H. Sohn, P.H. Lee (Wonju, Korea)

    Objective: We investigated whether patients with persistent drug-induced parkinsonism (DIP) showing visually normal dopamine transporter (DAT) imaging had minimal changes in striatal DAT activity using…
  • 2016 International Congress

    A survey of movement disorders in a large sample of patients treated with antipsychotic medication

    B. Balint, H. Killaspy, T.R.E. Barnes, N. Freemantle, E. Joyce, D. Martino, K.P. Bhatia (London, United Kingdom)

    Objective: To describe the prevalence and nature of movement disorders (MD) in a large sample of patients treated with antipsychotic medication. Background: Although there are…
  • « Previous Page
  • 1
  • …
  • 7
  • 8
  • 9
  • 10
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Nilotinib for treating MSA: A preclinical proof of concept study
  • Life expectancy with and without Parkinson’s disease in the general population
  • An atypical and interesting feature of Parkinson´s disease
  • Patients with Essential Tremor Live Longer than their Relatives
    • Effect of marijuana on Essential Tremor: A case report
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
    • Patients with Essential Tremor Live Longer than their Relatives
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley